eMIMS New Product

New drug - Tasigna

23-Jun-08

Novartis has launched Tasigna (nilotinib), a new antineoplastic agent for Philadelphia chromosome positive chronic myelogenous leukaemia (CML).

Treatment is indicated for adults with chronic-phase and accelerated-phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib.

View Tasigna drug record

Further information: Novartis 01276 692255

Comments

Only registered users may comment. Log in now or register for a free account.

Login to comment


forgotten your password?